Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04521712 · ClinicalTrials.gov registry record · NA
Postpartum Glycemia in Women At Risk for Persistent Hyperglycemia
A NA study, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- NA
- Development phase
- 40
- Enrollment target
NCT04521712 is a NA study that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 40 participants.
The verdict
NCT04521712, a NA study, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- NA
- Development phase
- 40 participants
- Enrollment target
Study Summary
GDM is characterized by decreased insulin sensitivity, decreased insulin secretion, or a combination of both. Women with GDM are at significant risk for overt T2DM later in life, and postpartum insulin sensitivity and secretion in women with GDM has not been quantified, limiting our ability to optimize screening for overt T2DM. In addition, compliance with currently recommended postpartum T2DM screening by OGTT is poor. Quantification of postpartum insulin sensitivity and secretion in women at high risk for T2DM will inform strategies to improve diagnostic strategies. Continuous glucose monitoring (CGM) is a new technology that may be useful to identify women with persistent hyperglycemia. Understanding maternal glycemia and physiology that drives glycemia in the postpartum period is limited. Completion of this study will define postpartum maternal glycemia, quantify insulin secretion versus insulin sensitivity defects, and demonstrate the feasiblity of using continuous glucose monitoring to identify women most at risk for overt T2DM.
Interventions
- DIAGNOSTIC_TEST 2-hour 75-g oral glucose tolerance test and Dexcom G6 Pro continuous glucose monitor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2021-09-17 |
| Est. Completion | 2024-12-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04521712
The ClinicalTrials.gov registry entry for NCT04521712 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 2-hour 75-g oral glucose tolerance test and Dexcom G6 Pro continuous glucose monitor is the first listed.
NCT04521712 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04521712 about?
NCT04521712 is a clinical study titled "Postpartum Glycemia in Women At Risk for Persistent Hyperglycemia". GDM is characterized by decreased insulin sensitivity, decreased insulin secretion, or a combination of both. Women with GDM are at significant risk for overt T2DM later in life, and postpartum insulin sensitivity and secretion in women with GDM has not been quantified, limiting our ability to optim...
What is the current status of trial NCT04521712?
This trial is currently completed. It is a NA study. The enrollment target is 40 participants. The study started on 2021-09-17. Estimated completion is 2024-12-10.
What interventions are being tested in trial NCT04521712?
The interventions under investigation include: 2-hour 75-g oral glucose tolerance test and Dexcom G6 Pro continuous glucose monitor (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04521712?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.